Overview of biological therapy in ulcerative colitis: current and future directions.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Gastrointestinal and Liver Diseases

• Publication date

  2015-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.15403/jgld.2014.1121.242.bezzPMID 26114181
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?

  2014cited by this paper
• Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy.

  2014cited by this paper
• Therapy of inflammatory bowel disease: what to expect in the next decade

  2014cited by this paper
• Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis

  2014cited by this paper
• Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

  2014cited by this paper
• Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3

  2014cited by this paper
• Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.

  2014cited by this paper
• Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis

  2014cited by this paper
• Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis.

  2014cited by this paper
• Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.

  2014cited by this paper
• Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

  2014cited by this paper
• Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis

  2014cited by this paper
• Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

  2014cited by this paper
• Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis

  2014cited by this paper
• Induction and maintenance therapy with vedolizumab, a novel biologic therapy for ulcerative colitis.

  2014cited by this paper
• Biological Agents for Moderately to Severely Active Ulcerative Colitis

  2014cited by this paper
• Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

  2014cited by this paper
• Golimumab in unresponsive ulcerative colitis

  2014cited by this paper
• Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab

  2013cited by this paper
• Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.

  2013cited by this paper
• One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

  2013cited by this paper
• Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis

  2013cited by this paper
• Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience

  2013cited by this paper
• Review article: strategies for the management of chronic unremitting ulcerative colitis

  2013cited by this paper
• Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.

  2013cited by this paper
• ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).

  2013cited by this paper
• 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants

  2013cited by this paper
• Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future

  2013cited by this paper
• Vedolizumab as induction and maintenance therapy for ulcerative colitis.

  2013cited by this paper
• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

  2012cited by this paper
• Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study

  2012cited by this paper
• Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

  2012cited by this paper
• Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

  2012cited by this paper
• Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus.

  2012cited by this paper
• Ulcerative colitis as a progressive disease: the forgotten evidence.

  2012cited by this paper
• Mucosal healing with infliximab: results from the active ulcerative colitis trials.

  2012cited by this paper
• Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

  2012cited by this paper
• Abatacept for Crohn's disease and ulcerative colitis.

  2012cited by this paper
• Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

  2012cited by this paper
• Adalimumab in active ulcerative colitis: a "real-life" observational study.

  2012cited by this paper
• Immunosuppressive and biologic therapy for ulcerative colitis

  2012cited by this paper
• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

  2011cited by this paper
• Future therapeutic approaches for inflammatory bowel diseases.

  2011cited by this paper
• Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

  2011cited by this paper
• Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis.

  2011cited by this paper
• Successive Treatment With Cyclosporine and Infliximab in Steroid-Refractory Ulcerative Colitis

  2011cited by this paper
• The Impact of Ulcerative Colitis on Patients’ Lives Compared to Other Chronic Diseases: A Patient Survey

  2010cited by this paper
• Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

  2010cited by this paper
• Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

  2010cited by this paper
• Open‐label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

  2009cited by this paper
• Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)

  2009cited by this paper
• Long‐term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single‐centre experience

  2008cited by this paper
• Long-term outcome after infliximab for refractory ulcerative colitis.

  2008cited by this paper
• Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.

  2008cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

  2003cited by this paper
• A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha‐4 integrin

  2002cited by this paper
• Course of ulcerative colitis: analysis of changes in disease activity over years.

  1994cited by this paper
• Clinical and Experimental Gastroenterology Dovepress Is There a Role for Vedolizumab in the Treatment of Ulcerative Colitis and Crohn's Disease?

  year unknowncited by this paper

• Evaluation of protective effect of the hydroalcoholic extract of aerial parts of Amaranthus spinosus on acetic acid induced colitis in mice via modulating inflammatory markers and oxidative stress.

  2025cites this paper
• Effect of Biologic Therapies in Treating Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis

  2025cites this paper
• Early-Phase Partial Mayo Score following Golimumab Treatment Is Associated with Endoscopic Improvement at 1 Year in Ulcerative Colitis: A post hoc Analysis of PURSUIT-J Randomized Controlled Trial

  2022cites this paper
• Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study

  2020cites this paper
• Application of Polymeric Nano-Materials in Management of Inflammatory Bowel Disease.

  2020cites this paper
• Organometallic Compounds and Metal Complexes in Current and Future Treatments of Inflammatory Bowel Disease and Colorectal Cancer—a Critical Review

  2019cites this paper
• Flightless I exacerbation of inflammatory responses contributes to increased colonic damage in a mouse model of dextran sulphate sodium-induced ulcerative colitis

  2019cites this paper
• Anti-tumour necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease

  2018cites this paper
• Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease.

  2018cites this paper
• Suppression of inflammation and tissue damage by a hookworm recombinant protein in experimental colitis

  2017cites this paper
• Protective effect of cardamonin against acetic acid-induced ulcerative colitis in rats

  2017cites this paper
• Schiff base complexes of copper and zinc as potential anti-colitic compounds

  2017cites this paper
• The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology

  2017cites this paper
• Personalizing IBD Therapy: The Asian Perspective

  2016cites this paper
• Chlor-amidine, a novel PAD inhibitor, as an effective drug for the treatment of ulcerative colitis and prevention of colorectal cancer

  2016cites this paper
• Moxibustion regulates inflammatory mediators and colonic mucosal barrier in ulcerative colitis rats.

  2016cites this paper
• INFLAMMATORY BOWEL DISEASE : HOW CAN TRADITIONAL THERAPY HELP ?

  2015cites this paper